Tejnaksh Healthcare Ltd Upgraded to Sell on Improved Valuation Metrics

Quality Assessment: Persistent Fundamental Weakness

Tejnaksh Healthcare continues to grapple with weak long-term fundamentals. Over the past five years, the company has recorded a negative compound annual growth rate (CAGR) of -5.68% in operating profits, signalling deteriorating operational efficiency. The average Return on Equity (ROE) stands at a modest 9.52%, reflecting limited profitability relative to shareholders’ equity. The latest quarterly results for Q3 FY25-26 were largely flat, underscoring the absence of meaningful growth momentum.

Further compounding concerns is the company’s low debtors turnover ratio of 4.87 times for the half-year period, indicating slower collection cycles and potential working capital inefficiencies. This ratio is among the lowest in its peer group, suggesting operational challenges in managing receivables effectively.

In comparison to benchmark indices, Tejnaksh Healthcare has consistently underperformed. The stock has delivered a negative return of -30.72% over the last year, significantly lagging the BSE500 index and the Sensex, which posted declines of -8.84% and -11.71% respectively over similar periods. Over three and five years, the stock’s returns have been deeply negative at -60.09% and -55.40%, while the Sensex has appreciated by 20.68% and 54.39% respectively. This persistent underperformance highlights the company’s struggle to generate shareholder value.

Valuation Upgrade: From Attractive to Very Attractive

The primary catalyst for the rating upgrade is the marked improvement in valuation metrics. Tejnaksh Healthcare’s valuation grade has been upgraded from attractive to very attractive, reflecting a more compelling entry point for investors. The company’s price-to-earnings (PE) ratio stands at 21.81, which is significantly lower than several peers such as Suraksha Diagnostics (PE 47.86) and KMC Speciality (PE 42.43). This discount is further emphasised by the price-to-book value of 1.13, indicating the stock is trading close to its book value and at a relative bargain compared to sector averages.

Enterprise value (EV) multiples also support this valuation thesis. The EV to EBITDA ratio is 10.51, well below the levels seen in competitors like Gujarat Kidney (EV/EBITDA 70.09) and Gaudium IVF (28.65). The EV to EBIT multiple of 19.03 and EV to capital employed of 1.13 further reinforce the stock’s undervaluation. Notably, the PEG ratio is reported as 0.00, which may indicate either zero or negligible earnings growth expectations, aligning with the company’s flat financial trend.

Return on Capital Employed (ROCE) at 8.28% and the latest ROE of 6.34% remain modest but are consistent with the valuation discount. The stock’s current price of ₹15.04 is near its 52-week low of ₹10.65, far from the 52-week high of ₹23.31, signalling a depressed market sentiment that has been priced in.

Financial Trend: Flat Performance Amid Declining Profitability

Despite the valuation appeal, Tejnaksh Healthcare’s financial trend remains subdued. The company reported flat results in the December 2025 quarter, with no significant improvement in revenue or profitability. Over the past year, profits have declined by approximately 41.2%, exacerbating concerns about the company’s ability to reverse its earnings trajectory.

The weak financial trend is also reflected in the stock’s returns, which have been negative across multiple time horizons. The one-month return of -1.70% slightly outperformed the Sensex’s -3.68%, but this is a short-term anomaly in an otherwise negative performance record. The year-to-date return is a marginal positive 0.33%, contrasting with the Sensex’s decline of -11.71%, largely due to the stock’s depressed base price rather than operational improvement.

Technical Analysis: Mixed Signals with Slight Positive Momentum

From a technical standpoint, Tejnaksh Healthcare’s stock price has shown limited volatility today, with a day change of +0.33%. The intraday high was ₹15.15 and the low ₹14.71, indicating a narrow trading range. While this suggests some stability, the stock remains well below its 52-week high, reflecting a lack of sustained bullish momentum.

The stock’s micro-cap status and relatively low liquidity may contribute to muted technical signals. The absence of strong upward price movement or volume spikes implies that technical indicators have not yet confirmed a robust recovery. However, the slight positive price change and the upgrade in valuation grade may attract value-oriented investors seeking turnaround opportunities.

Comparative Industry Context and Market Capitalisation

Operating within the healthcare services sector, Tejnaksh Healthcare is classified as a micro-cap company, which inherently carries higher volatility and risk compared to larger peers. Its Mojo Score of 31.0 and Mojo Grade of Sell reflect the cautious stance adopted by analysts, despite the recent upgrade from Strong Sell. The company’s valuation remains very attractive relative to its peers, many of whom trade at significantly higher multiples, underscoring the market’s scepticism about Tejnaksh’s growth prospects.

Majority ownership by promoters continues to be a stabilising factor, but the lack of operational improvement and consistent underperformance against benchmarks such as the Sensex and BSE500 indices weigh heavily on investor sentiment.

Conclusion: Valuation Improvement Insufficient to Offset Weak Fundamentals

In summary, Tejnaksh Healthcare Ltd’s upgrade from Strong Sell to Sell is primarily driven by a more attractive valuation profile, offering a potentially better risk-reward balance for investors. However, the company’s weak financial trends, low profitability, and persistent underperformance relative to market benchmarks remain significant concerns. Technical indicators provide limited encouragement, with only marginal positive price movement observed.

Investors considering exposure to Tejnaksh Healthcare should weigh the valuation appeal against the ongoing operational challenges and subdued growth outlook. The stock’s micro-cap status and sector dynamics further necessitate a cautious approach, favouring those with a higher risk tolerance and a long-term investment horizon.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →